Clinical Trial

A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation

Recruiting
View on ClinicalTrials.gov →
Summary
To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-09-26; most recent amendment 2025-11-05.
Status change: Not Yet Recruiting → Recruiting 2024-01-25
Trial Details
NCT Number NCT06059963
Lead Sponsor Universal Diagnostics
Conditions Colorectal Cancer, Advanced Adenocarcinoma
Enrollment 12,000 participants
Start Date 2024-01-18
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-10